Top Markets
#1 Black Phoenix Black Phoenix +354.79%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +76.58%
#4 Gold Park Gold Park +61.59%
#5 OpenEden OpenEden +47.95%
#6 Acurast Acurast +32.33%
#7 BasedHype BasedHype +27.12%
#8 Cryptopia Cryptopia +21.54%
#9 Avantis Avantis +20.48%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +20.03%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Alligator Bioscience AB (publ) Alligator Bioscience AB (publ)

Alligator Bioscience AB (publ)

ATORX
Rank in Stocks #40436
Alligator Bioscience AB (publ) is a research-intensive biotechnology company... Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its drug development. These include ALLIGATOR-GOLD and ALLIGATOR-FAB, an extensive human antibody library boasting roughly 60 billion distinct antibody fragments; FIND, a molecular evolution technique used for optimizing antibodies and other proteins; and RUBY, a specialized format for creating bispecific antibodies. Alligator Bioscience's pipeline features several promising candidates. In the clinical stage, Mitazalimab, an immunostimulatory CD40 antibody, has successfully completed Phase I trials for metastatic cancer. Also undergoing Phase I clinical evaluation is ATOR-1017, another immunostimulatory antibody designed to bind to the 4-1BB receptor on tumor-specific T cells. For its preclinical efforts, the company is advancing ALG.APV-527, a bispecific antibody targeting both 4-1BB and 5T4 for cancer therapy. Additionally, Alligator Bioscience holds an interest in the Biosynergy (AC101) project, which is currently in Phase I. To bolster its research and development capabilities, Alligator Bioscience has formed multiple strategic collaborations. It has a co-development partnership with Aptevo Therapeutics Inc. for ALG.APV-527, and a research alliance with MacroGenics, Inc. to create novel immunotherapies. Further collaborations include a joint research agreement with BioArctic AB (publ) to utilize proprietary antibody generation technologies for new product candidates, and a research and license agreement with Orion Corporation aimed at discovering and developing new bispecific antibody cancer therapeutics. The company was established in 2000.
Share Price
$0.00408798
Market Cap
$147.44K
Change (1 day)
-0.54%
Change (1 year)
-99.17%
Country
SE
Trade Alligator Bioscience AB (publ) (ATORX)

Category

Healthcare
Operating Margin for Alligator Bioscience AB (publ) (ATORX)
Operating Margin as of 2026 TTM: 0.00%
According to Alligator Bioscience AB (publ) latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Alligator Bioscience AB (publ) from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.